Agalimmune licenses KODE Biotech’s FSL technology for development of cancer immunotherapeutics
16 June 2015 | By Victoria White
Agalimmune has licensed KODE Biotech’s Function-Spacer-Lipid (FSL) cell surface membrane modification technology (KODE™ Technology)...